Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bomedemstat versus best available therapy in hydroxyurea-resistant or -intolerant essential thrombocythemia
ChiCTR2400089201Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in thrombocythemia (2 arms), sponsored by Union Hospital. Primary endpoint: Durable clinicohematologic response. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on ChiCTR2400089201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089201.